Nanotechnology-mediated targeting of tumor angiogenesis

Vascular Cell

Volumn 3, Issue , 2011, Pages

  Banerjee, Deboshri ^a   Harfouche, Rania ^a   Sengupta, Shiladitya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALENDRONIC ACID; ANGINEX; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ARGINYLGLYCYLASPARTIC ACID; COMBRETASTATIN; CURCUMIN; DOXORUBICIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GOLD NANOPARTICLE; INTEGRIN ALPHAVBETA3 ANTIBODY; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYETHYLENEIMINE; PROTEINASE ACTIVATED RECEPTOR 1; QUANTUM DOT; RECEPTOR ANTIBODY; SHORT HAIRPIN RNA; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN 121; VASCULOTROPIN RECEPTOR 1; VATALANIB; VITRONECTIN RECEPTOR; YTTRIUM 90;

ANGIOGENESIS; ANTIANGIOGENIC GENE THERAPY; ANTIANGIOGENIC THERAPY; BINDING AFFINITY; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE METASTASIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COMBINATORIAL CHEMISTRY; COMPETITIVE INHIBITION; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG UPTAKE; FLUORESCENCE IMAGING; HUMAN; LIPOSOMAL DELIVERY; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; NANOENCAPSULATION; NANOTECHNOLOGY; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TARGET CELL DESTRUCTION; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

HARNESS;

EID: 79955622231     PISSN: 2045824X     EISSN: None     Source Type: Journal    
DOI: 10.1186/2045-824X-3-3     Document Type: Review

References (103)

1. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. Weidner N Semple JP, Welch WR Folkman J, N Engl J Med 1991 324 1 8 10.1056/NEJM199101033240101 1701519
2. Mechanisms of angiogenesis. Risau W, Nature 1997 386 671 674 10.1038/386671a0 9109485 (Pubitemid 27193480)
3. Angiogenesis in cancer, vascular, rheumatoid and other disease. Folkman J, Nat Med 1995 1 27 31 10.1038/nm0195-27 7584949
4. Tumor angiogenesis: therapeutic implications. Folkman J, N Engl J Med 1971 285 1182 1186 10.1056/NEJM197108122850711 4938153
5. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Naumov GN Akslen LA Folkman J, Cell Cycle 2006 5 1779 1787 10.4161/cc.5.16.3018 16931911 (Pubitemid 44435320)
6. Mathematical modelling of angiogenesis. Chaplain MA, J Neurooncol 2000 50 37 51 10.1023/A:1006446020377 11245280 (Pubitemid 32166289)
7. Incipient angiogenesis 1. Folkman J, J Natl Cancer Inst 2000 92 94 95 10.1093/jnci/92.2.94 10639502
8. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma 1. Weidner N Folkman J, Pozza F Bevilacqua P, Allred EN Moore DH, Meli S Gasparini G, J Natl Cancer Inst 1992 84 1875 1887 10.1093/jnci/84.24.1875 1281237 (Pubitemid 23004615)
9. Imaging angiogenesis and the microenvironment. Fukumura D Jain RK, APMIS 2008 116 695 715 10.1111/j.1600-0463.2008.01148.x 18834413
10. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Boudreau N Myers C, Breast Cancer Res 2003 5 140 146 10.1186/bcr589 12793895 (Pubitemid 36519407)
11. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. Khodarev NN Yu J Labay E Darga T, Brown CK Mauceri HJ, Yassari R Gupta N, Weichselbaum RR, J Cell Sci 2003 116 1013 1022 10.1242/jcs.00281 12584245 (Pubitemid 36395612)
12. Integrins in cancer: biological implications and therapeutic opportunities. Desgrosellier JS Cheresh DA, Nat Rev Cancer 2010 10 9 22 10.1038/nrc2748 20029421
13. Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Yeh CH Peng HC Huang TF, Blood 1998 92 3268 3276 9787163 (Pubitemid 28492334)
14. Angiogenesis: regulators and clinical applications. Liekens S De Clercq E Neyts J, Biochem Pharmacol 2001 61 253 270 10.1016/S0006-2952(00)00529-3 11172729 (Pubitemid 32126663)
15. Nanocarriers as an emerging platform for cancer therapy. Peer D Karp JM, Hong S Farokhzad OC, Margalit R Langer R, Nat Nanotechnol 2007 2 751 760 10.1038/nnano.2007.387 18654426 (Pubitemid 350223348)
16. VEGF as a therapeutic target in cancer. Ferrara N, Oncology 2005 69 Suppl 3 11 16 10.1159/000088479 16301831 (Pubitemid 41680948)
17. Fundamental concepts of the angiogenic process. Folkman J, Curr Mol Med 2003 3 643 651 10.2174/1566524033479465 14601638 (Pubitemid 37236406)
18. Design and development of polymer conjugates as anti-angiogenic agents. Segal E Satchi-Fainaro R, Adv Drug Deliv Rev 2009 61 1159 1176 10.1016/j.addr.2009.06.005 19699248
19. The anti-angiogenic basis of metronomic chemotherapy. Kerbel RS Kamen BA, Nat Rev Cancer 2004 4 423 436 10.1038/nrc1369 15170445 (Pubitemid 38745528)
20. Nanoparticle therapeutics: an emerging treatment modality for cancer. Davis ME Chen ZG Shin DM, Nat Rev Drug Discov 2008 7 771 782 10.1038/nrd2614 18758474
21. Nanotechnology-based drug delivery systems. Suri SS Fenniri H Singh B, J Occup Med Toxicol 2007 2 16 10.1186/1745-6673-2-16 18053152
22. Impact of nanotechnology on drug delivery. Farokhzad OC Langer R, ACS Nano 2009 3 16 20 10.1021/nn900002m 19206243
23. Nanotechnology: intelligent design to treat complex disease. Couvreur P Vauthier C, Pharm Res 2006 23 1417 1450 10.1007/s11095-006-0284-8 16779701 (Pubitemid 43993807)
24. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Satchi-Fainaro R Mamluk R Wang L Short SM, Nagy JA Feng D, Dvorak AM Dvorak HF, Puder M Mukhopadhyay D, Folkman J, Cancer Cell 2005 7 251 261 10.1016/j.ccr.2005.02.007 15766663 (Pubitemid 40568684)
25. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Satchi-Fainaro R Puder M, Davies JW Tran HT, Sampson DA Greene AK, Corfas G Folkman J, Nat Med 2004 10 255 261 10.1038/nm1002 14981512 (Pubitemid 38667615)
26. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Sengupta S Eavarone D Capila I Zhao G, Watson N Kiziltepe T, Sasisekharan R, Nature 2005 436 568 572 10.1038/nature03794 16049491 (Pubitemid 41112931)
27. Shape effect of carbon nanovectors on angiogenesis. Chaudhuri P Harfouche R Soni S Hentschel DM, Sengupta S, ACS Nano 2010 4 574 582 10.1021/nn901465h 20043662
28. Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis. Harfouche R Basu S, Soni S Hentschel DM, Mashelkar RA Sengupta S, Angiogenesis 2009 19685150
29. Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Anderson SA Rader RK, Westlin WF Null C, Jackson D Lanza GM, Wickline SA Kotyk JJ, Magn Reson Med 2000 44 433 439 10.1002/1522-2594(200009)44:3<433::AID-MRM14>3.0.CO;2-9 10975896
30. Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. Park JH Kwon S Nam JO Park RW, Chung H Seo SB, Kim IS Kwon IC, Jeong SY, J Control Release 2004 95 579 588 10.1016/j.jconrel.2003.12.020 15023468 (Pubitemid 38340507)
31. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Winter PM Morawski AM Caruthers SD Fuhrhop RW, Zhang H Williams TA, Allen JS Lacy EK, Robertson JD Lanza GM, Wickline SA, Circulation 2003 108 2270 2274 10.1161/01.CIR.0000093185.16083.95 14557370 (Pubitemid 37363046)
32. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Waters EA Chen J Yang X Zhang H, Neumann R Santeford A, Arbeit J Lanza GM, Wickline SA, Magn Reson Med 2008 60 1232 1236 10.1002/mrm.21794 18956417
33. Substrate specificity of the heparan sulfate hexuronic acid 2-O-sulfotransferase. Rong J Habuchi H Kimata K Lindahl U, Kusche-Gullberg M, Biochemistry 2001 40 5548 5555 10.1021/bi002926p 11331020 (Pubitemid 32458257)
34. Tumor angiogenic endothelial cell targeting by a novel integrin-targeted nanoparticle. Xie J Shen Z, Li KC Danthi N, Int J Nanomedicine 2007 2 479 485 18019845 (Pubitemid 350047790)
35. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. Buehler A van Zandvoort MA Stelt BJ Hackeng TM, Schrans-Stassen BH Bennaghmouch A, Hofstra L Cleutjens JP, Duijvestijn A Smeets MB, de Kleijn DP Post MJ, de Muinck ED, Arterioscler Thromb Vasc Biol 2006 26 2681 2687 10.1161/01.ATV.0000245807.65714.0b 16990557
36. Significance of soluble endothelial molecule E-selectin in patients with breast cancer. Hebbar M Peyrat JP, Int J Biol Markers 2000 15 15 21 10763135 (Pubitemid 30195477)
37. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Kang HW Josephson L Petrovsky A Weissleder R, Bogdanov A Jr, Bioconjug Chem 2002 13 122 127 10.1021/bc0155521 11792187 (Pubitemid 34119643)
38. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Wagner S Rothweiler F Anhorn MG Sauer D, Riemann I Weiss EC, Katsen-Globa A Michaelis M, Cinatl J Schwartz D, Kreuter J von BH, Langer K, Biomaterials 2010 31 2388 2398 10.1016/j.biomaterials.2009.11.093 20031203
39. Nanoparticles - a new colloidal drug delivery system. Marty JJ Oppenheim RC Speiser P, Pharm Acta Helv 1978 53 17 23 643885
40. Incorporation of polylactide-polyglycolide in a cortical defect: neoangiogenesis and blood supply in a bone chamber. Winet H Hollinger JO Stevanovic M, J Orthop Res 1995 13 679 689 10.1002/jor.1100130507 7472746
41. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. Couvreur P Kante B, Roland M Speiser P, J Pharm Sci 1979 68 1521 1524 10.1002/jps.2600681215 529043 (Pubitemid 10183437)
42. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. Segal E Pan H Ofek P Udagawa T, Kopeckova P Kopecek J, Satchi-Fainaro R, PLoS ONE 2009 4 5233 10.1371/journal.pone.0005233 19381291
43. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Miller K Erez R Segal E Shabat D, Satchi-Fainaro R, Angew Chem Int Ed Engl 2009 48 2949 2954 10.1002/anie. 200805133 19294707
44. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. Mitra A Mulholland J, Nan A McNeill E, Ghandehari H Line BR, J Control Release 2005 102 191 201 10.1016/j.jconrel.2004.09.023 15653145 (Pubitemid 40093785)
45. Polymeric conjugates of mono- and bi-cyclic alphaVbeta3 binding peptides for tumor targeting. Mitra A Coleman T, Borgman M Nan A, Ghandehari H Line BR, J Control Release 2006 114 175 183 10.1016/j.jconrel.2006.06.014 16889865 (Pubitemid 44291848)
46. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Basu S Harfouche R, Soni S Chimote G, Mashelkar RA Sengupta S, Proc Natl Acad Sci USA 2009 106 7957 7961 10.1073/pnas.0902857106 19383798
47. PEGylation, successful approach to drug delivery. Veronese FM Pasut G, Drug Discov Today 2005 10 1451 1458 10.1016/S1359-6446(05)03575-0 16243265 (Pubitemid 41483874)
48. Transparent adult zebrafish as a tool for in vivo transplantation analysis. White RM Sessa A Burke C Bowman T, LeBlanc J Ceol C, Bourque C Dovey M, Goessling W Burns CE, Zon LI, Cell Stem Cell 2008 2 183 189 10.1016/j.stem.2007.11.002 18371439 (Pubitemid 351168711)
49. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Anand P Nair HB Sung B Kunnumakkara AB, Yadav VR Tekmal RR, Aggarwal BB, Biochem Pharmacol 2010 79 330 338 10.1016/j.bcp.2009.09.003 19735646
50. Dendrimers and dendritic polymers in drug delivery. Gillies ER Frechet JM, Drug Discov Today 2005 10 35 43 10.1016/S1359-6446(04)03276-3 15676297 (Pubitemid 40164817)
51. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism. Xu Y Wen Z Xu Z, Anticancer Res 2009 29 5103 5109 20044623
52. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Backer MV Gaynutdinov TI Patel V Bandyopadhyaya AK, Thirumamagal BT Tjarks W, Barth RF Claffey K, Backer JM, Mol Cancer Ther 2005 4 1423 1429 10.1158/1535-7163.MCT-05-0161 16170035
53. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Benny O Fainaru O, Adini A Cassiola F, Bazinet L Adini I, Pravda E Nahmias Y, Koirala S Corfas G, D'Amato RJ Folkman J, Nat Biotechnol 2008 26 799 807 10.1038/nbt1415 18587385 (Pubitemid 351961454)
54. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Nasongkla N Shuai X Ai H Weinberg BD, Pink J Boothman DA, Gao J, Angew Chem Int Ed Engl 2004 43 6323 6327 10.1002/anie.200460800 15558662 (Pubitemid 40029462)
55. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oku N Asai T, Watanabe K Kuromi K, Nagatsuka M Kurohane K, Kikkawa H Ogino K, Tanaka M Ishikawa D, Tsukada H Momose M, Nakayama J Taki T, Oncogene 2002 21 2662 2669 10.1038/sj.onc.1205347 11965539 (Pubitemid 34478324)
56. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. Asai T Shimizu K, Kondo M Kuromi K, Watanabe K Ogino K, Taki T Shuto S, Matsuda A Oku N, FEBS Lett 2002 520 167 170 10.1016/S0014-5793(02)02821-1 12044891 (Pubitemid 34607294)
57. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. Maeda N Takeuchi Y, Takada M Sadzuka Y, Namba Y Oku N, J Control Release 2004 100 41 52 10.1016/j.jconrel.2004.07.033 15491809 (Pubitemid 39445984)
58. Antineovascular therapy, a novel antiangiogenic approach. Shimizu K Asai T Oku N, Expert Opin Ther Targets 2005 9 63 76 10.1517/14728222.9.1.63 15757482 (Pubitemid 40331197)
59. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Li L Wartchow CA Danthi SN Shen Z, Dechene N Pease J, Choi HS Doede T, Chu P Ning S, Lee DY Bednarski MD, Knox SJ, Int J Radiat Oncol Biol Phys 2004 58 1215 1227 10.1016/j.ijrobp.2003. 10.057 15001266 (Pubitemid 38314807)
60. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Hatakeyama H Akita H, Ishida E Hashimoto K, Kobayashi H Aoki T, Yasuda J Obata K, Kikuchi H Ishida T, Kiwada H Harashima H, Int J Pharm 2007 342 194 200 10.1016/j.ijpharm.2007.04.037 17583453 (Pubitemid 47259319)
61. Carbon inhibits vascular endothelial growth factor-and fibroblast growth factor-promoted angiogenesis. Murugesan S Mousa SA O'connor LJ Lincoln DW, Linhardt RJ, FEBS Lett 2007 581 1157 1160 10.1016/j.febslet.2007.02.022 17331505 (Pubitemid 46385938)
62. Antiangiogenic properties of gold nanoparticles. Mukherjee P Bhattacharya R Wang P Wang L, Basu S Nagy JA, Atala A Mukhopadhyay D, Soker S, Clin Cancer Res 2005 11 3530 3534 10.1158/1078-0432.CCR-04-2482 15867256 (Pubitemid 40627908)
63. Antiangiogenic properties of silver nanoparticles. Gurunathan S Lee KJ, Kalishwaralal K Sheikpranbabu S, Vaidyanathan R Eom SH, Biomaterials 2009 30 6341 6350 10.1016/j.biomaterials.2009.08.008 19698986
64. Targeted delivery of multifunctional magnetic nanoparticles. McCarthy JR Kelly KA, Sun EY Weissleder R, Nanomedicine (Lond) 2007 2 153 167 10.2217/17435889.2.2.153 17716118 (Pubitemid 46850565)
65. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Chen J Wu H, Han D Xie C, Cancer Lett 2006 231 169 175 10.1016/j.canlet.2005.01.024 16399221 (Pubitemid 43038727)
66. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Maeng JH Lee DH Jung KH Bae YH, Park IS Jeong S, Jeon YS Shim CK, Kim W Kim J, Lee J Lee YM, Kim JH Kim WH, Hong SS, Biomaterials 2010 31 4995 5006 10.1016/j.biomaterials.2010.02.068 20347138
67. Angiogenesis modulation in cancer research: novel clinical approaches. Cristofanilli M Charnsangavej C Hortobagyi GN, Nat Rev Drug Discov 2002 1 415 426 10.1038/nrd819 12119743 (Pubitemid 37361484)
68. Modified natural nanoparticles as contrast agents for medical imaging. Cormode DP Jarzyna PA, Mulder WJ Fayad ZA, Adv Drug Deliv Rev 2010 62 329 338 10.1016/j.addr.2009.11.005 19900496
69. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Drevs J Muller-Driver R, Wittig C Fuxius S, Esser N Hugenschmidt H, Konerding MA Allegrini PR, Wood J Hennig J, Unger C Marme D, Cancer Res 2002 62 4015 4022 12124335 (Pubitemid 34791068)
70. Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model. Reichardt W Hu-Lowe D Torres D Weissleder R, Bogdanov A Jr, Neoplasia 2005 7 847 853 10.1593/neo.05139 16229807
71. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Sipkins DA Cheresh DA, Kazemi MR Nevin LM, Bednarski MD Li KC, Nat Med 1998 4 623 626 10.1038/nm0598-623 9585240 (Pubitemid 28237365)
72. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Mulder WJ Strijkers GJ Habets JW Bleeker EJ, van der Schaft DW Storm G, Koning GA Griffioen AW, Nicolay K, FASEB J 2005 19 2008 2010 16204353 (Pubitemid 41759747)
73. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. Mulder WJ van der Schaft DW Hautvast PA Strijkers GJ, Koning GA Storm G, Mayo KH Griffioen AW, Nicolay K, FASEB J 2007 21 378 383 10.1096/fj.06-6791com 17202248 (Pubitemid 46213485)
74. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Kluza E van der Schaft DW, Hautvast PA Mulder WJ, Mayo KH Griffioen AW, Strijkers GJ Nicolay K, Nano Lett 2010 10 52 58 10.1021/nl902659g 19968235
75. Micro-CT imaging of breast tumors in rodents using a liposomal, nanoparticle contrast agent. Samei E Saunders RS Badea CT Ghaghada KB, Hedlund LW Qi Y, Yuan H Bentley RC, Mukundan S Jr, Int J Nanomedicine 2009 4 277 282 10.2147/IJN.S7881 20011244
76. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Mulder WJ Koole R Brandwijk RJ Storm G, Chin PT Strijkers GJ, de Mello DC Nicolay K, Griffioen AW, Nano Lett 2006 6 1 6 10.1021/nl051935m 16402777 (Pubitemid 43166093)
77. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Oostendorp M Douma K Hackeng TM Dirksen A, Post MJ van Zandvoort MA, Backes WH, Cancer Res 2008 68 7676 7683 10.1158/0008-5472.CAN-08-0689 18794157
78. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Manchester M Singh P, Adv Drug Deliv Rev 2006 58 1505 1522 10.1016/j.addr.2006.09.014 17118484 (Pubitemid 44829893)
79. Multivalent display and receptor-mediated endocytosis of transferrin on virus-like particles. Banerjee D Liu AP Voss NR Schmid SL, Finn MG, Chembiochem 2010 11 1273 1279 10.1002/cbic.201000125 20455239
80. Viral nanoparticles as tools for intravital vascular imaging. Lewis JD Destito G Zijlstra A Gonzalez MJ, Quigley JP Manchester M, Stuhlmann H, Nat Med 2006 12 354 360 10.1038/nm1368 16501571 (Pubitemid 43355086)
81. Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. Brunel FM Lewis JD Destito G Steinmetz NF, Manchester M Stuhlmann H, Dawson PE, Nano Lett 2010 10 1093 1097 10.1021/nl1002526 20163184
82. Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Geninatti CS Bussolati B, Tei L Grange C, Esposito G Lanzardo S, Camussi G Aime S, Cancer Res 2006 66 9196 9201 10.1158/0008-5472.CAN-06-1728 16982763 (Pubitemid 44521140)
83. Soluble Flt-1 gene delivery using PEI-g-PEG-RGD conjugate for anti-angiogenesis. Kim WJ Yockman JW, Lee M Jeong JH, Kim YH Kim SW, J Control Release 2005 106 224 234 10.1016/j.jconrel.2005.04.016 15970348 (Pubitemid 41140097)
84. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. Kim WJ Yockman JW Jeong JH Christensen LV, Lee M Kim YH, Kim SW, J Control Release 2006 114 381 388 10.1016/j.jconrel.2006.05.029 16884805 (Pubitemid 44310812)
85. Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Hadj-Slimane R Lepelletier Y Lopez N Garbay C, Raynaud F, Biochimie 2007 89 1234 1244 10.1016/j.biochi.2007.06.012 17707573 (Pubitemid 47498688)
86. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Schiffelers RM Ansari A, Xu J Zhou Q, Tang Q Storm G, Molema G Lu PY, Scaria PV Woodle MC, Nucleic Acids Res 2004 32 149 10.1093/nar/gnh140 15520458
87. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Villares GJ Zigler M Wang H Melnikova VO, Wu H Friedman R, Leslie MC Vivas-Mejia PE, Lopez-Berestein G Sood AK, Bar-Eli M, Cancer Res 2008 68 9078 9086 10.1158/0008-5472.CAN-08-2397 18974154
88. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Pille JY Li H, Blot E Bertrand JR, Pritchard LL Opolon P, Maksimenko A Lu H, Vannier JP Soria J, Malvy C Soria C, Hum Gene Ther 2006 17 1019 1026 10.1089/hum.2006.17.1019 17007568 (Pubitemid 46076743)
89. The future of aptamers in medicine. Khati M, J Clin Pathol 2010 20360137
90. Molecular diagnostic and drug delivery agents based on aptamer-nanomaterial conjugates. Lee JH Yigit MV, Mazumdar D Lu Y, Adv Drug Deliv Rev 2010 20338204
91. Peptide aptamers: tools for biology and drug discovery. Crawford M Woodman R Ko FP, Brief Funct Genomic Proteomic 2003 2 72 79 10.1093/bfgp/2.1.72 15243998
92. Aptamer biosensor for protein detection using gold nanoparticles. Wang W Chen C, Qian M Zhao XS, Anal Biochem 2008 373 213 219 10.1016/j.ab.2007.11.013 18054771
93. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Estevez MC Huang YF, Kang H O'Donoghue MB, Bamrungsap S Yan J, Chen X Tan W, Methods Mol Biol 2010 624 235 248 full-text 20217600
94. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Smith JE Medley CD, Tang Z Shangguan D, Lofton C Tan W, Anal Chem 2007 79 3075 3082 10.1021/ac062151b 17348633 (Pubitemid 46640529)
95. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Carrasquillo KG Ricker JA, Rigas IK Miller JW, Gragoudas ES Adamis AP, Invest Ophthalmol Vis Sci 2003 44 290 299 10.1167/iovs.01-1156 12506087 (Pubitemid 36134287)
96. Liposome-anchored vascular endothelial growth factor aptamers. Willis MC Collins BD Zhang T Green LS, Sebesta DP Bell C, Kellogg E Gill SC, Magallanez A Knauer S, Bendele RA Gill PS, Janjic N, Bioconjug Chem 1998 9 573 582 10.1021/bc980002x 9736491
97. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. White RR Shan S Rusconi CP Shetty G, Dewhirst MW Kontos CD, Sullenger BA, Proc Natl Acad Sci USA 2003 100 5028 5033 10.1073/pnas.0831159100 12692304 (Pubitemid 36542652)
98. Signaling and regulation of endothelial cell survival by angiopoietin-2. Harfouche R Hussain SN, Am J Physiol Heart Circ Physiol 2006 291 1635 H1645 10.1152/ajpheart.01318.2005 16714355
99. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Mern DS Hoppe-Seyler K Hoppe-Seyler F Hasskarl J, Burwinkel B, Breast Cancer Res Treat 2010 20191379
100. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Zhao BM Hoffmann FM, Mol Biol Cell 2006 17 3819 3831 10.1091/mbc.E05-10-0990 16775010 (Pubitemid 44330868)
101. Prevention of carbon nanohorn agglomeration using a conjugate composed of comb-shaped polyethylene glycol and a peptide aptamer. Matsumura S Sato S Yudasaka M Tomida A, Tsuruo T Iijima S, Shiba K, Mol Pharm 2009 6 441 447 10.1021/mp800141v 19718797
102. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Anderson SA Glod J Arbab AS Noel M, Ashari P Fine HA, Frank JA, Blood 2005 105 420 425 10.1182/blood-2004-06-2222 15331444 (Pubitemid 40053114)
103. Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles. Yang F Cho SW, Son SM Bogatyrev SR, Singh D Green JJ, Mei Y Park S, Bhang SH Kim BS, Langer R Anderson DG, Proc Natl Acad Sci USA 2010 107 3317 3322 10.1073/pnas.0905432106 19805054